{"id":"W3028216699","doi":"10.1002/oby.22794","title":"Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5","year":2020,"lang":"en","type":"article","venue":"Obesity","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"ca_institutions":"York University","funders":"NIHR Leicester Biomedical Research Centre; Mitsubishi Tanabe Pharma Corporation; Servier; Eisai; Zafgen; Astellas Pharma; Mylan; MannKind Corporation; Bausch Health; University of Pennsylvania; Novo Nordisk; National Institute for Health and Care Research; Intarcia Therapeutics; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Waist; Placebo; Overweight; Obesity; Type 2 diabetes; Tolerability; Weight loss; Population; Circumference; Clinical trial; Physical therapy; Internal medicine; Diabetes mellitus; Adverse effect; Alternative medicine; Endocrinology; Liraglutide; Environmental health","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01000939,0.0009170217,0.001771678,0.0003937418,0.0005401606,0.001563688,0.0009926249,0.001891046,0.01057074],"category_scores_gemma":[0.008091476,0.00034528,0.002419657,0.0004942743,0.0005484575,0.001266561,0.001067083,0.003021106,0.001910732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007991681,"about_ca_system_score_gemma":0.002704091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006930709,"about_ca_topic_score_gemma":0.002460622,"domain_scores_codex":[0.9960383,0.002631664,0.0004654174,0.0001948709,0.0004798569,0.0001898589],"domain_scores_gemma":[0.9971173,0.0008980029,0.0005761992,0.0001641026,0.0006049511,0.0006395254],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2990663,0.007956884,0.005507282,0.02239195,0.006484605,0.0002644529,0.0003463742,0.0008462655,0.008634513,0.005399377,0.0608581,0.5822439],"study_design_scores_gemma":[0.5722879,0.1577239,0.02765631,0.01567302,0.008800872,0.0005824185,0.0002954682,0.001589454,0.006132314,0.00655457,0.2025368,0.0001670776],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.3743129,0.3204772,0.01631572,0.0737894,0.01193922,0.1029589,0.01641723,0.001160198,0.08262931],"genre_scores_gemma":[0.6169645,0.135261,0.05662577,0.04995643,0.005600466,0.1007693,0.01185725,0.000299169,0.02266615],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.01057074,"threshold_uncertainty_score":0.05293536,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06482362611717103,"score_gpt":0.3124158583845207,"score_spread":0.2475922322673497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}